Teva regulatory update

TEVIY received a review letter from the U.K. Medicines Control Agency (MCA) as part of the agency's review of Copaxone copolymer-1 for the treatment of multiple sclerosis. The MCA did not request additional data. The letter also addressed several unspecified issues that the company said it believed it could answer adequately. TEVIY said it has scheduled meetings with the MCA in the next few weeks. ...